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average age was 56.5 years old, 53.2% are female, 54.3% are white, 80.9% have less 
than a degree, 69.3% make less than R$6,500 annually, 68.4% have public insurance, 
and 73.5% are overweight or obese. Regarding HbA1c levels, only 4.0% were controlled, 
5.4% were uncontrolled, and 90.6% were unknown. Additionally, 17.0% experienced 
recent hypoglycemia, 69.6% did not, and 13.5% did not know. The majority were taking 
diabetes medication (86.4%), but only 37.2% were adherent. ConClusions: Although 
most Brazilian DM2 respondents are currently taking prescription medication, few are 
adherent to their medication and have adequate knowledge about their symptoms. 
Considering public health implications of diabetes, awareness, education programs, 
and pharmaceutical care for DM2 patients may improve adherence to treatment.
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objeCtives: Hypoglycemic episodes, symptoms presented by patients with 
diabetes mellitus type II (DM2), are associated with increased mortality and 
decreased health-related quality of life (HRQoL). However, few studies on hypo-
glycemia and its relationship to outcomes exist in Brazil. This study investigated 
the association of hypoglycemia episodes with health outcomes for Brazilian DM2 
patients. Methods: Data are analyzed from the 2011, 2012, & 2014 Brazil National 
Health and Wellness Survey (NHWS), an internet-based general health survey 
stratified to be representative of age and gender. Among 33,082 total respondents, 
1,565 reported having been diagnosed with DM2. Respondents were categorized 
into groups based on hypoglycemic episodes in the past three months: not experi-
enced (n= 1,100) and experienced (n= 259). Those whose hypoglycemia was unknown 
(n= 206) were excluded from analyses. Outcomes included HRQoL, work produc-
tivity loss, and healthcare resource use in the past 6 months. Generalized linear 
models were used to control for demographic and health characteristics. Results: 
Recent hypoglycemia was experienced by 16.5% of DM2 respondents (age= 53.47 
year; 46.0% female) in Brazil. Controlling for covariates, those with recent hypo-
glycemia reported worse mean HRQoL for mental (43.78 vs. 47.38), physical (43.92 
vs. 47.16), and health utility (0.645 vs. 0.696) scores compared with respondents 
who did not recently experience hypoglycemia. Respondents with recently (vs. not 
recently) experienced hypoglycemia also reported higher mean presenteeism (33.5% 
vs. 20.6%), overall work impairment (37.27% vs. 24.75%), and activity impairment 
(40.73% vs. 27.90%). Lastly, those with recently (vs. not recently) experienced hypo-
glycemia reported higher mean number of doctor visits (8.53 vs. 5.87), emergency 
room visits (0.92 vs. 0.65), and hospitalizations (0.53 vs. 0.26). ConClusions: Recent 
hypoglycemia episodes are associated with significant burden in HRQoL, health-
care resource use, work-related productivity loss and activity impairment. These 
Resultssupport the need for development of health strategies to improve outcomes 
related to DM2 in Brazil.
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objeCtives: The current study aimed to determine the prevalence of 
Complementary and Alternative Medicines (CAM) and its types used in diabetes 
patients in Quetta, Pakistan. Methods: A cross-sectional study was undertaken 
with diabetes patients, attending different government and private hospitals and 
clinic of Quetta city, Pakistan. A self-administered questionnaire containing 16 
questions (5questions related with disease and remaining questions were for 
information regarding CAM use). Descriptive statistics were applied to evaluate 
the patient’s demographics. Inferential statistics were used to fine the association 
between demographics characteristics and CAM (p< 0.05). Results: A total of 500 
questionnaires were distributed and 451 were returned (with response rate of 
90.2%). Out of 451 patients 148 (32.8%) used CAM for the diabetes treatment, out of 
which 87 (58.8%) were females and 61 (41.2%) were males. Most of the participants 
were uneducated 51 (34.5%) and belongs to large families 89 (60.1%). Fifty (33.8%) 
participants were using mind body intervention, followed by alternative medical 
system (33.1%) and herbal products (31.8%) respectively for treatment of diabetes. 
Type of family, monthly income and per month medicine cost were significant 
associated (p< 0.05) with CAM use. ConClusions: The current study indicated 
that diabetes patients used mind body intervention, alternative medical system 
and herbal products are the most common CAM type used for diabetes control. 
Further research is recommended to evaluate the diabetes control in patients 
with CAM used.
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objeCtives: The objective of current study is to determine the purpose, belief and 
perception on CAM use by diabetic patients. This study also highlights the rate of 
CAM disclosure to physician Methods: A cross-sectional study was undertaken 
with 148 participants, attending using CAM as mode of treatment in Quetta city, 
Pakistan. A self-administered questionnaire containing 16 questions was used. five 
questions were about diabetes, while remaining questions were on information 
regarding CAM use. Descriptive statistics were applied to evaluate the patient’s 
a personas con DMT2, complementaria al control y tratamiento de la enfermedad a 
través de pares, es costo-efectiva respecto a la de educación tradicional.
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objeCtivos: evaluar la costo-efectividad y costo-utilidad del uso del undecanoato 
de testosterona como terapia de reemplazo y coadyuvancia en pacientes con hipog-
onadismo asociado a diabetes mellitus tipo 2 en Colombia, desde la perspectiva del 
tercero pagador. MetodologíAs: se diseñó un modelo de Markov tipo Montecarlo, 
donde se simula la historia natural del hipogonadismo asociado a diabetes mel-
litus tipo 2, por medio de una cohorte de 1000 pacientes donde se simulan las var-
iaciones en HbA1c trimestralmente y acorde a estas el riesgo de desarrollar eventos 
macrovasculares o muerte en un horizonte temporal de diez años. Los parámetros 
fueron utilizados según los intervalos de confianza de los estudios clínicos y los 
costos se estimaron a partir de bases de datos de aseguradores y presentados en 
pesos colombianos del 2014. Se corrieron 10.000 iteraciones del modelo y los resul-
tados son presentados en términos de años de vida ajustados por calidad y años de 
vida. ResultAdos: el uso de undecanoato de testosterona mostró mayor efectivi-
dad tanto en años de vida (7,83) como en años de vida ajustados por calidad (6,32) 
con respecto a no tratar el hipogonadismo que fue de 7,74 y 6,24 para un paciente 
diabético promedio. Con respecto a los costos, el tratar con undecanoato de testos-
terona se estimó en $16.860.744 frente a $14.060.358 de un paciente sin tratami-
ento. Al aplicar una tasa de descuento del 5% anual las razones de costo-efectividad 
incremental serían de $28.310.750 por años de vida salvados y $35.794.244 por años 
de vida ajustados por calidad, valores que estarían por debajo del umbral aceptado 
para Colombia. ConClusiones: el uso del undecanoato de testosterona es costo-
efectivo para pacientes con hipogonadismo asociado a diabetes mellitus tipo 2 en 
Colombia, bajo los desenlaces de años de vida y años de vida ajustados por calidad 
en las condiciones analizadas.
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objeCtives: To investigate the relationship of different dimensions of diabetes with 
employment chances, labour income and working hours using panel data and biomarker 
information for Mexico. Methods: I use three waves (2002, 2005, 2009) of the Mexican 
Family Life Survey to estimate panel data fixed effects models of the relationship of 
self-reported diabetes and diabetes duration with labour market outcomes. Further, 
using glycated hemoglobin (HbA1c) measurements from a sub-sample of survey partici-
pants in 2009, I investigate how this relationship changes according to diabetes severity 
and if there are differences between diagnosed and undiagnosed people with diabe-
tes Results: I find robust evidence for a reduction in employment chances of about 5 
percentage points (pp) (p< 0.05) for Mexican men and women, while I find no effects for 
wages or working hours. I also find evidence that the main adverse effects appear within 
the first two years after diagnosis for women and after about 15 years after diagnosis 
for men. For diabetes severity, the main adverse effects are found for those with self-
reported diabetes and an HbA1c between 6.5%–8%. For undiagnosed diabetes no effects 
are found. ConClusions: I find robust evidence that diabetes reduces employment 
chances for men and women in Mexico. The relationship does not appear to be linear 
with diabetes duration and appears early after diagnosis for women and relatively late 
for men. So far I find no strong evidence that the severity of diabetes could be an impor-
tant driver of these adverse effects, however, this last part of the analysis is limited by 
the cross-sectional nature of the biomarker data and its reduced sample size. Overall, 
the Resultsare indicative of an employment penalty of diabetes that might not be solely 
driven by the health effects of diabetes.
DiaBetes/enDocRine DisoRDeRs – Patient-Reported outcomes & Patient 
Preference studies
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objeCtives: Diabetes mellitus type II (DM2), a highly prevalent disease worldwide, 
negatively impacts public health. However, epidemiology data regarding DM2 are very 
scarce in Brazil. This study aims to understand DM2 prevalence and control of dia-
betic symptoms, such as HbA1c levels and hypoglycemia, in Brazil. Methods: Data 
were derived from the 2011 & 2012 Brazil National Health and Wellness Survey, an 
internet-based general health survey, stratified to be representative of age and gender. 
Among 24,000 total respondents, 1,026 reported a DM2 diagnosis, further subdivided 
by HbA1c levels: “controlled,” indicated by HbA1c< 7% (n= 57); “uncontrolled,” indi-
cated by HbA1c≥ 7% (n= 67); and unknown HbA1c (n= 902). Additionally, respondents 
were categorized by hypoglycemia experience in the past three months: not experi-
enced (n= 186), experienced (n= 701), and unknown (n= 139). The Morisky Medication 
Adherence Scale-4 was used to categorize respondents with no non-adherent behav-
iors regarding their diabetes medication as “adherent.” Resultswere weighted to be rep-
resentative of the adult Brazilian population. One-way ANOVAs and chi-squares were 
used to examine group differences. Results: In Brazil, projected estimates reveal that 
4.0% (n= 5,585,272) of the adult population have a DM2 diagnosis. Of those diagnosed, 
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objeCtivos: Evaluar el impacto sobre el presupuesto anual de salud de Chile por la 
inclusión de Daclatasvir/Asunaprevir (DCV/ASV) para el tratamiento de la Hepatitis 
C genotipo 1b. MetodologíAs: Se modeló la cohorte de pacientes Chilenos con 
Hepatitis C genotipo 1b utilizando datos de prevalencia e incidencia locales de acu-
erdo a la metodología sugerida por la guía de buenas prácticas ISPOR. Se comparó el 
escenario en el que todos los pacientes reciben Peginterferon/Ribavirina (PR) versus 
el escenario donde todos los pacientes son tratados con DCV/ASV. El análisis fue 
realizado desde la perspectiva del sistema de salud público Chileno asumiendo 100% 
de cobertura de los fármacos. Se introdujeron costos asociados al tratamiento farma-
cológico, de eventos adversos, recursos relevantes (monitoreo mediante exámenes 
de laboratorio, anatomía patológica, imágenes y controles médicos) y costos asocia-
dos a complicaciones de la enfermedad. Se consideró un horizonte de tiempo de 5 
años. ResultAdos: El impacto sobre el presupuesto anual (tomando como base el 
de 2015) se presenta para tres precios posibles de DCV/ASV. A CL$1.500.000 pesos 
chilenos (CL$) semanales se requieren CL$42.928.668.276 adicionales el primer año 
(tratamiento de casos prevalentes) lo que equivale a un 0.71% del presupuesto anual. 
Desde el año 2 en adelante (asumiendo tratar sólo casos incidentes) el monto asciende 
a CL$8.031.019.832 adicionales (0,13% del presupuesto nacional 2015). A CL$1.000.000 
semanal, se requieren CL$25.015.902.617 adicionales el primer año y CL$4.679.931.106 
adicionales desde el año 2 (0,11% y 0,6% del presupuesto anual de salud 2015). A 
CL$500.000 semanales se requieren CL$ 7.103.136.957 adicionales el primer año y 
CL$1.328.842.381 adicionales a partir del segundo año (0,3% y al 0,057% del presu-
puesto nacional 2015 respectivamente). ConClusiones: En los rangos de precios 
estudiados, el impacto sobre el presupuesto de salud chileno oscila entre el 0,3% y 
0,71% para el primer año, el cual disminuiría a menos del 0,15% desde el segundo año.
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Inflammatory bowel disease (IBD) is associated with high costs, high morbidity and 
decreased quality of life in patients. In Mexico and Brazil, there is no concise data 
about prevalence of Crohn´s Disease (CD) estimated to range from 0.0008% to 1.11% 
and no cost data attributable to IBD.objeCtives: To assess the average annual cost per 
patient with CD treated with biologics from the perspective of the government health-
care system both in Mexico and Brazil. Methods: Biologic treatments examined 
included certolizumab pegol (CZP) 400 mg weeks 0, 2, 4 and then every 4 weeks; adali-
mumab (ADA) 160 mg week 0, 80 mg week 2 and then 40 mg every 2 weeks; infliximab 
(INF) 5 mg / kg at weeks 0, 2, 6, and every 8 weeks thereafter. Medication acquisition 
costs were assessed for CZP and ADA, while costs for INF assessed both acquisition 
and administration (infusion). Average weight per patient in the analyses was 70kg. 
Prices were obtained from the Mexican Social Security Institute (IMSS) and ANVISA 
for Brazil. Exchange rates were obtained from public sources (1USD= 0.0675MXN; 
1USD= 2.7BRL). Results: The analysis for Mexico shows lower costs in the first year 
of treatment (induction and maintenance) with CZP (USD$7,719/year) vs ADA and INF 
(USD$12,792, USD$17,313/year, respectively), leading to cost savings per patient/year 
compared with CZP of approximately USD$5,073 and USD$9,594 versus adalimumab 
and infliximab. In Brazil, similar Resultswere seen: CZP (USD$7,186/year) versus ADA 
(USD$24,813/year) and INF (USD$31,004/year), showing savings with CZP of USD$17,627 
vs ADA and USD$23,818 vs INF per year. The savings are even greater with CZP in the 
maintenance years. ConClusions: Certolizumab pegol shows savings when com-
pared to adalimumab and infliximab in the first year of treatment and maintenance, 
which can lead to an important impact on institutional budgets.
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objeCtives: Comparing efficacy and costs of treatment strategies using terli-
pressin or noradrenaline for cirrhotic patients with hepatorenal syndrome, under 
the perspectives of Brazilian public health system, a major general hospital and a 
major private health insurance. Methods: Comparison of efficacy was performed 
through a systematic review with meta-analysis of randomized controlled trials, 
using random-effects model. Economic evaluation was performed through cost-
minimization. Results: Four studies (154 patients) were included in the meta-
analysis. There was no evidence of difference between treatments with terlipressin 
or noradrenaline regarding 30-day survival (risk ratio of 1.04, 95% confidence inter-
val of 0.84-1.30, p= 0.70). Under the perspective of the public health system, costs of 
treatments with terlipressin or noradrenaline were 287.77 and 2,960.45 International 
Dollars (Int$) respectively. Under the perspective of the general hospital, costs of 
the treatments with terlipressin or noradrenaline were Int$7,437.04 and Int$8,406.41 
respectively. Regarding the perspective of the private health insurance, costs of treat-
ments with terlipressin and noradrenaline were Int$13,484.57 and Int$15,061.01 
respectively. ConClusions: There was no evidence of superiority between treat-
ment strategies using terlipressin or noradrenaline regarding survival of patients 
with hepatorenal syndrome, but the strategy using terlipressin was more economical 
under three different perspectives.
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demographics. Results: The total number of CAM users were 148, out of which 
87 (58.8%) were females and 61 (41.2%) were males. Most of the participants (n= 51, 
34.5%) were uneducated and belongs to large families (n= 89, 60.1%). Most of par-
ticipants use CAM to lower their glycemic level, majority (n= 125, 84.5%) of which 
belief that CAM can lower their sugar level. However, only 12% of the participants 
disclose this CAM use to their physician. ConClusions: The finding of current 
study indicates that most of diabetic CAM users population belief that CAM can con-
trol their glycemic level. However, the rate of CAM disclosure to physician was very 
low. Efforts should be made to encourage their diabetic CAM user to disclose their 
CAM use to their physician so he will give them better advise for gycemic control.
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objeCtives: The study aims were to investigate patient’s preferences in clinical 
outcomes and patient burden to administer insulin injections, as measured by 
patients’ willingness to pay (WTP). Methods: Existing national email panels in 
Argentina, Brazil, Chile, Colombia and Mexico were used to collect survey-based 
data from adults > 18 years with type 2 diabetes (T2DM) treated with insulin injec-
tions. Resultswere analysed using a standard choice model designed for discrete 
choice experiment (DCE). Clinical outcomes related to efficacy (reduction in HbA1c) 
and safety (severe (SH) and non-severe hypoglycaemic (NSH) events and change in 
weight) and the patient burden of insulin administration (preparation of insulin 
prior to injecting and number of daily injections) were found to be relevant fac-
tors in qualitative research in patients and were examined in the DCE. Results: 
A total of 1537 people (54% males) with T2DM completed the survey. Participants 
placed high monetary value on efficacy and safety outcomes; they would pay 74 
USD/month to reduce HbA1c by 1% and 80 USD/month to reduce one SH event per 
year. To reduce one NSH per week participants were willing to pay 91 USD/month. 
Participants wanting to lose weight reported a WTP of 37 USD/month to lose 3 kg. 
To avoid preparation of insulin prior to injection, participants reported a WTP of 18 
USD/month and the WTP/month for one fewer injection/day was 25 USD. Potential 
limitations of this study are that preferences expressed may not match preferences 
in real-life situations, and bias through recruiting via internet panels since these 
may not be representative of typical patients. ConClusions: Clinical outcomes 
and administrative burden were significant predictors of choice in people with 
T2DM. Reducing HbA1c as well as number of SH and NSH were the highest valued 
outcomes. In addition, the administrative burden of insulin injections was also 
considered important.
DiaBetes/enDocRine DisoRDeRs – Health care use & Policy studies
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objeCtives: Patient education is a key component for the management of acute 
and chronic conditions. However, majority of such educational sessions are reported 
from the healthcare settings. The present study therefore, aims to evaluate whether 
a home-based intervention can result in better understanding about Diabetes 
Mellitus Type 2 and can increase medication adherence to the prescribed thera-
pies. Methods: A non-clinical randomized control trial was conducted whereby 
participants received a home-based educational intervention through a registered 
pharmacist. Diabetes knowledge and medication adherence were measured by 
means of self-administered questionnaires. Descriptive statistics were used to 
describe the demographic and disease characteristics of the patients. Inferential 
statistics were used for inter- and intra- group comparisons. SPSS 18 was used 
for data analysis. P< 0.05 was taken as significant. Results: One hundred and 
fifty patients were randomly assigned to two groups (75 patients in each arm). No 
significant differences were observed in either group for demographic variables. 
There was, however, a significant increase in the participants’ levels of knowledge 
about Diabetes Mellitus type 2 and medication adherence among the Home-based 
intervention group at the completion of the intervention (p< 0.001). Significantly 
lower HbA1c levels were also observed among the Home-based intervention group 
after completion of the intervention (p< 0.001). ConClusions: Pharmacist-led 
home-based intervention can significantly increase disease-related knowledge 
and medication adherence in patients with type 2 diabetes mellitus. This study 
hereby concludes that home-based interventional programs should be utilized as 
a compelling method of patient education and counselling.
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